However, increased BCMA expression during B-cell differentiation, especially in late memory B cells and normal plasma cells, heightens the risk of off-target effects (i.e., targeting normal cells instead of the tumor) [51]. The gene discussed is TNFRSF17; the disease is neoplasm.